Skip to main content

Table 3 Overview of those who Completed, Refused or Died during the Study

From: Participation of older newly-diagnosed cancer patients in an observational prospective pilot study: an example of recruitment and retention

Characteristic Completed the study
N = 90 (%)
Died during study
N = 15 (%)
Refused follow-up
N = 7 (%)
Mean age at baseline interview (SD) 73.6 year
SD (6.2)
72.9 year
SD (4.6)
76.7 year
SD (6.0)
Sex    
Female 66 9 6
Male 24 6 1
Marital status    
Married or living common-law 46 12 4
Widowed 22 2 1
Separated/divorced 18 0 1
Single 4 1 1
No Information 0 0 0
Lives alone    
Yes 37 5 3
No 53 10 4
Born in Canada    
Yes 50 11 4
No 40 4 3
Type of cancer/alive at end of study and completed study    
Lung 19/19 (100%) 8 0
Breast 41/44 (93.2%) 0 3
Colorectal 14/18 (77.8%) 24 4
Lymphoma 13/13 (100%) 1 0
Multiple myeloma 3/3 (100%) 0 0
Extent of disease at diagnosis    
Early (stage 0–2) 55 2 6
Advanced (stage 3–4) 35 13 1
Enrolled into clinical trial    
Yes 7 14 7
No 83 1 0
Treatment proposed    
Watchful waiting 2 0 0
Surgery 47 1 6
Chemotherapy 29 13 0
  9 1 0
Radiation therapy
Hormonal therapy
3 0 1
Cancer diagnosis    
First diagnosis 79 14 7
Recurrence 2 0 0
New diagnosis, not first diag. 9 1 0
Ecog Performance scale at baseline    
0 65 (72.2) 2 (13.3) 5 (71.4)
1 14 (15.6) 6 (40.0) 2 (28.6)
2 9 (10.0) 3 (20.0) 0
3 2 (2.2) 4 (26.7) 0
4. 0 0 0
Mood impairment (HADS A or D ≥ 10) 18 (20.0) 7 (46.7) 1 (14.3)
Cognitive impairment (MMSE ≤ 26 or Moca ≤ 26) 3 (3.3) 3 (20.0) 2 (28.6)
IADL disability (OARS) 27 (30.0) 8 (53.3) 4 (57.1)
ADL disability (Katz) 7 (7.8) 4 (26.7) 1 (14.3)
Mean number of self-reported comorbid conditions (Functional comorbidity Index) 2.0 (SD 1.9) 3.3 (SD 2.5) 1.9 (SD 1.2)